Therapies for Infantile Haemangiomas: Current Practice and Evolving Perspectives - Summary - MDSpire

Therapies for Infantile Haemangiomas: Current Practice and Evolving Perspectives

  • By

  • B. Nolan

  • C. O’Connor

  • May 9, 2026

  • 0 min

Share

Objective:

To review current management strategies for infantile haemangiomas (IH) and highlight emerging insights in treatment, emphasizing the need for individualized care.

Key Findings:
  • Propranolol is the first-line treatment for problematic IH with high efficacy.
  • Alternative beta-blockers may offer benefits in specific cases.
  • Topical treatments are limited to small superficial lesions.
  • Teledermatology enhances access to care.
Interpretation:

The management of infantile haemangiomas has evolved significantly, with propranolol leading as the preferred treatment option due to its effectiveness and safety profile.

Limitations:
  • Not all IH require treatment, and management must be individualized.
  • Potential adverse effects of beta-blockers need consideration.
Conclusion:

Propranolol has revolutionized the treatment of infantile haemangiomas, emphasizing the need for early identification and intervention in high-risk cases.

Original Source(s)

Therapies for Infantile Haemangiomas: Current Practice and Evolving Perspectives

  • by B. Nolan, C. O’Connor

  • May 9, 2026

Related Content

GLP-1 Agents May Reduce Psoriasis Severity

National Psoriasis Foundation review highlights limited evidence and potential metabolic links.

AI Falls Short on Differential Dx

New PrIME-LLM benchmark shows strong diagnostic accuracy but persistent gaps in clinical reasoning across 21 large language models

Cupping vs UVB: Comparable Psoriasis Outcomes?

Randomized study found no statistically significant differences in disease improvement between treatments over 8 weeks.